The ROC Payment Receipt and Its Six-Month Validity
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Nicaragua sets the validity of the payment receipt (Recibo Oficial de Caja, ROC) at a maximum of six months from the date of payment. Item 1 of Chapter 6 and Article 1(b) of Chapter 8 of NTON 24001:2023, the latter dealing with renewals, are worded identically: a receipt issued more than six months after payment is not accepted and the fee must be paid again. The fee schedule rests on Resolución Ministerial N° 347-2023. The practical consequence is that the payment must fall inside the submission window, not at the point when dossier preparation begins.
- The six-month clock starts on the date the fee is paid, not on the date the receipt is issued or the date of submission.
- An expired receipt has no remedy other than a fresh payment; there is no extension and no mechanism for paying a difference.
- The registration fee and the first-import quality analysis fee are two separate payments, and each is managed against its own six-month horizon.
- If a corrected submission consumes six months, the receipt can expire even where the application itself has not been cancelled.
- Amounts are not reproduced here: they follow the current official publication under RM 347-2023.
2. Legal basis
The provisions below show how the six-month rule is anchored twice in the standard, once for new registrations and once for renewals, and how the fee itself is delegated to a separate ministerial resolution rather than fixed in the standard.
| Level | Instrument | Provision | Key point |
| Technical standard | NTON 24001:2023, Tecnología de la salud. Dispositivos médicos. Requisitos para el Registro Sanitario (La Gaceta No. 192, 21 October 2024) | Chapter 6, item 1 | The ROC is valid for a maximum of six months from the date of payment; receipts older than six months are not accepted and the fee must be paid again |
| Technical standard | NTON 24001:2023 | Chapter 8, Article 1(b) | The same six-month validity rule applies to the ROC for renewal |
| Technical standard | NTON 24001:2023 | Chapter 5, Article 10 | The registration processing fee is determined by the corresponding legal provisions |
| Fee schedule | Resolución Ministerial N° 347-2023, Lista actualizada de pago por servicios que presta el Instituto de Investigación en Salud (INIS), SILAIS y las instancias de la Autoridad Nacional de Regulación Sanitaria | Whole text | Fee schedule; amounts follow the current official publication |
| Administrative resolution | Resolución Administrativa N° 0007/2025 (in force from 2 May 2025) | Annex I, Article 12, item 3 | Where an application is cancelled for failure to correct within the deadline, it must be resubmitted and restarts from payment |
| Technical standard | NTON 24001:2023 | Chapter 7, Article 8 | First-import quality analysis is charged separately, on the same RM 347-2023 basis |
3. Expert insights
Insight 1: the six months run desde la cancelación del pago del arancel, that is, from payment of the fee. It is neither the date the receipt was issued nor the date of submission. If half a year separates payment from submission, the receipt has already lapsed.
Insight 2: the consequence of lapse is a fresh payment. The text states no será aceptado y deberá realizarse el pago nuevamente, with no extension and no mechanism for paying the difference. This is one of the few clauses in the checklist that offers no remedy at all.
Insight 3: the registration fee and the quality analysis fee are two distinct payments. Item 1 of Chapter 6 governs the registration processing fee, while Article 8 of Chapter 7 and note two to Article 14 of Annex I to RA 0007/2025 govern the first-import quality analysis fee; both point to RM 347-2023. Budgets should carry both lines, each managed on its own six-month basis.
Insight 4: combined with the correction deadlines, the payment date enters the critical path. A single cancellation means paying again, and the ROC lasts only six months. If the correction stage consumes six months, the receipt lapses even where the application survives, forcing a second payment. If the correction windows of fifteen working days at preliminary review and twenty working days at evaluation are both used in full, the time pressure becomes visible.
Insight 5: the fee instrument itself carries the word actualizada, updated, in its full title, Lista actualizada de pago por servicios. The official PDF obtained for this volume is a scan without a text layer, so the amounts cannot be verified line by line. This volume therefore lists no amounts and refers the reader to the current official publication.
Insight 6: Article 10 of Chapter 5 delegates the fee to the corresponding legal provisions, and RA 0007/2025 and its annexes then point to RM 347-2023. The chain means that adjusting fees does not require amending the NTON itself: the standard dates from 2023, while the fee schedule can be updated independently.
4. Practical recommendations
- Schedule payment after the dossier is complete and before submission, not at the start of dossier preparation.
- Record the payment date in the tracking sheet, set a reminder at six months, and check the position again immediately before submission.
- Budget two lines: the registration processing fee and the first-import quality analysis fee, corresponding to item 1 of Chapter 6 and Article 8 of Chapter 7 respectively.
- Monitor the ROC validity during the correction stage: if correction would cross the six-month mark, assess whether continuing or paying again is the more economical route.
- Take amounts exclusively from the current official publication under RM 347-2023, never from historical figures or second-hand summaries.
- Where an application is cancelled, restart from payment under Article 12, item 3, of Annex I, and bring the new payment date back into the six-month monitoring.
5. Verification checklist
- □ Payment is scheduled after the dossier is complete and before submission
- □ The payment date is recorded and a six-month expiry reminder is in place
- □ The budget lists the registration processing fee and the first-import quality analysis fee as two separate lines
- □ ROC validity is monitored alongside the correction stage
- □ All amounts come from the current official publication under RM 347-2023, with no historical figures used
- □ In the event of cancellation, payment has been restarted under Annex I, Article 12, item 3, and monitoring reset
Related reading: [Three SAJ approvals: legal representative, registration professional, distribution authorisation](/nicaragua-medical-device-registration/three-saj-approvals-for-powers/) | [CLV: issuing bodies, the two-year default validity and the legalisation chain](/nicaragua-medical-device-registration/certificate-of-free-sale-requirements/) | [The fee basis in RM 347-2023 and the payment milestones](/nicaragua-medical-device-registration/government-fees-and-rm-347-2023/)
Regulatory information verified as of 29 October 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us